Diabetes and Cardiovascular Disease Prevention in Older Adults

Clinics in Geriatric Medicine

Volumn 25, Issue 4, 2009, Pages 607-641

  Cigolle, Christine T ^a,b   Blaum, Caroline S ^a,b   Halter, Jeffrey B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Aging; Cardiovascular disease; Diabetes mellitus; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CAPTOPRIL; CHLORTALIDONE; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; LISINOPRIL; METFORMIN; MEVINOLIN; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PIOGLITAZONE; PLACEBO; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DYSLIPIDEMIA; ELDERLY CARE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LABORATORY TEST; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; REVIEW; RISK REDUCTION; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; EVIDENCE-BASED MEDICINE; HUMANS; LIFE STYLE; QUALITY OF LIFE; RISK FACTORS; SMOKING CESSATION;

EID: 70449864784     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2009.09.001     Document Type: Review

References (125)

1. Brown A.F., Mangione C.M., Saliba D., et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51 Suppl 5 (2003) S265-S280
2. Standards of medical care in diabetes-2009. Diabetes Care 32 Suppl 1 (2009) S13-S61
3. Percentage of civilian, noninstitutionalized population with diagnosed diabetes, by age, United States, 1980-2006. Available at: (2009). http://www.cdc.gov/diabetes/statistics/prev/national/figbyage.htm Accessed May 10, 2009
4. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007;2008.
5. Incidence of diagnosed diabetes per 1,000 population aged 18-79 years, by age, United States, 1980-2007. Available at. http://www.cdc.gov/diabetes/statistics/incidence/fig3.htm Accessed May 10, 2009
6. Scranton R.E., Dave J.K., and Gaziano J.M. Macrovascular complication of diabetes in older adults. In: Munshi M.N., and Lipsitz L.A. (Eds). Geriatric diabetes (2007), Informa Healthcare USA, Inc, New York 169-182
7. Barzilay J.I., Spiekerman C.F., Kuller L.H., et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care 24 7 (2001) 1233-1239
8. Kuller L.H., Arnold A.M., Psaty B.M., et al. 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med 166 1 (2006) 71-78
9. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 9323 (2002) 2072-2077
10. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 9541 (2006) 1096-1105
11. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
12. Kosaka K., Noda M., and Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67 2 (2005) 152-162
13. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20 4 (1997) 537-544
14. Ramachandran A., Snehalatha C., Mary S., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49 2 (2006) 289-297
15. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 1 (2004) 155-161
16. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 18 (2001) 1343-1350
17. Crandall J., Schade D., Ma Y., et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 61 10 (2006) 1075-1081
18. Nathan D.M., Davidson M.B., DeFronzo R.A., et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30 3 (2007) 753-759
19. Gaede P., Vedel P., Parving H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353 9153 (1999) 617-622
20. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 5 (2003) 383-393
21. Gaede P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 6 (2008) 580-591
22. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 24 (2008) 2545-2559
23. Goff Jr. D.C., Gerstein H.C., Ginsberg H.N., et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 12A (2007) 4i-20i
24. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 24 (2008) 2560-2572
25. Abraira C., Duckworth W., McCarren M., et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabet Complications 17 6 (2003) 314-322
26. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 2 (2009) 129-139
27. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 15 (2008) 1577-1589
28. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
29. Erdmann E., Dormandy J.A., Charbonnel B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 17 (2007) 1772-1780
30. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 9435 (2004) 685-696
31. Neil H.A., DeMicco D.A., Luo D., et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: collaborative atorvastatin diabetes study (CARDS). Diabetes Care 29 11 (2006) 2378-2384
32. Plummer C.J. What's in the CARDS?. Diabet Med 23 7 (2006) 711-714
33. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 9364 (2003) 1149-1158
34. Sever P.S., Dahlof B., Poulter N.R., et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19 6 (2001) 1139-1147
35. Sever P.S., Poulter N.R., Dahlof B., et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28 5 (2005) 1151-1157
36. Deedwania P., Barter P., Carmena R., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 9539 (2006) 919-928
37. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 14 (2005) 1425-1435
38. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 6 (2006) 1220-1226
39. Waters D.D., Guyton J.R., Herrington D.M., et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 2 (2004) 154-158
40. Ahmed S., Cannon C.P., Murphy S.A., et al. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J 27 19 (2006) 2323-2329
41. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
42. Cannon C.P., McCabe C.H., Belder R., et al. Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 89 7 (2002) 860-861
43. Arampatzis C.A., Goedhart D., Serruys P.W., et al. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention-a Lescol Intervention Prevention Study (LIPS) substudy. Am Heart J 149 2 (2005) 329-335
44. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 24 (2002) 3215-3222
45. Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 76 7 (1995) 474-479
46. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 19 (1998) 1349-1357
47. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 10 (2003) 2713-2721
48. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98 23 (1998) 2513-2519
49. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 14 (1996) 1001-1009
50. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 336 3 (1997) 153-162
51. Hoogwerf B.J., Waness A., Cressman M., et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes 48 6 (1999) 1289-1294
52. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 8934 (1994) 1383-1389
53. Haffner S.M. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 20 4 (1997) 469-471
54. Kjekshus J., and Pedersen T.R. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 76 9 (1995) 64C-68C
55. Pedersen T.R., Wilhelmsen L., Faergeman O., et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86 3 (2000) 257-262
56. Pyorala K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 4 (1997) 614-620
57. Knopp R.H., d'Emden M., Smilde J.G., et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 7 (2006) 1478-1485
58. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 20 10 (1999) 725-741
59. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
60. Collins R., Armitage J., Parish S., et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 9374 (2003) 2005-2016
61. Robins S.J., Rubins H.B., Faas F.H., et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Diabetes Care 26 5 (2003) 1513-1517
62. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 6 (1999) 410-418
63. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 22 (2002) 2597-2604
64. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 9500 (2005) 1849-1861
65. Scott R., Best J., Forder P., et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 4 (2005) 13
66. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 357 9260 (2001) 905-910
67. Steiner G. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group. Diabetologia 39 12 (1996) 1655-1661
68. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 9489 (2005) 895-906
69. Ostergren J., Poulter N.R., Sever P.S., et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 26 11 (2008) 2103-2111
70. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 23 (2002) 2981-2997
71. Davis B.R., Cutler J.A., Gordon D.J., et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 9 4 Pt 1 (1996) 342-360
72. Davis B.R., Furberg C.D., Wright Jr. J.T., et al. Setting the record straight. Ann Intern Med 141 1 (2004) 39-46
73. Varughese G.I., and Lip G.Y. Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists' Collaboration meta-analysis. J Hum Hypertens 19 11 (2005) 851-853
74. Whelton P.K., Barzilay J., Cushman W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 12 (2005) 1401-1409
75. Hansson L., and Zanchetti A. The Hypertension Optimal Treatment (HOT) Study-patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press 3 5 (1994) 322-327
76. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 9118 (1998) 1755-1762
77. Zanchetti A., Hansson L., Dahlof B., et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 19 6 (2001) 1149-1159
78. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 10 (1998) 645-652
79. Estacio R.O., and Schrier R.W. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 82 9B (1998) 9R-14R
80. Havranek E.P., Esler A., Estacio R.O., et al. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am Heart J 145 6 (2003) 993-998
81. Savage S., Johnson Nagel N., Estacio R.O., et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online J Curr Clin Trials 2 (1993) Doc No 104:[6250 words; 6128 paragraphs]
82. Schrier R.W., and Estacio R.O. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 343 26 (2000) 1969
83. Schrier R.W., Estacio R.O., Mehler P.S., et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 3 8 (2007) 428-438
84. Amery A., Birkenhager W., Bulpitt C.J., et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging (Milano) 3 3 (1991) 287-302
85. Gasowski J., Birkenhager W.H., Staessen J.A., et al. Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial. Cardiovasc Drugs Ther 14 1 (2000) 49-53
86. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 9080 (1997) 757-764
87. Staessen J.A., Fagard R., Thijs L., et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 158 15 (1998) 1681-1691
88. Tuomilehto J., Rastenyte D., Birkenhager W.H., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. systolic hypertension in Europe Trial Investigators. N Engl J Med 340 9 (1999) 677-684
89. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 24 (1991) 3255-3264
90. Holman R.R., Paul S.K., Bethel M.A., et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 15 (2008) 1565-1576
91. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 9590 (2007) 829-840
92. The BENEDICT Group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics. Control Clin Trials 24 4 (2003) 442-461
93. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 19 (2004) 1941-1951
94. Ruggenenti P., Iliev I., Costa G.M., et al. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 31 8 (2008) 1629-1634
95. Boner G., Cooper M.E., McCarroll K., et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 48 10 (2005) 1980-1987
96. Brenner B.M., Cooper M.E., de Zeeuw D., et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1 4 (2000) 328-335
97. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 12 (2001) 861-869
98. Kowey P.R., Dickson T.Z., Zhang Z., et al. Losartan and end-organ protection-lessons from the RENAAL study. Clin Cardiol 28 3 (2005) 136-142
99. Winkelmayer W.C., Zhang Z., Shahinfar S., et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 29 10 (2006) 2210-2217
100. Lievre M., Marre M., Chatellier G., et al. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. Control Clin Trials 21 4 (2000) 383-396
101. Marre M., Lievre M., Chatellier G., et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 328 7438 (2004) 495
102. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol 12 2 (1996) 127-137
103. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355 9200 (2000) 253-259
104. Dagenais G.R., Yusuf S., Bourassa M.G., et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 104 5 (2001) 522-526
105. Gerstein H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 18 Suppl 3 (2002) S82-S85
106. Salehian O., Healey J., Stambler B., et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 154 3 (2007) 448-453
107. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 1 1 (2000) 18-20
108. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
109. Sacco M., Pellegrini F., Roncaglioni M.C., et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26 12 (2003) 3264-3272
110. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357 9250 (2001) 89-95
111. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 18 (2008) 2134-2141
112. Dluhy R.G., and McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358 24 (2008) 2630-2633
113. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College Of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53 3 (2009) 298-304
114. Downs J.R., Beere P.A., Whitney E., et al. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 80 3 (1997) 287-293
115. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 20 (1998) 1615-1622
116. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 15 (1998) 1440-1445
117. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 9346 (2002) 1623-1630
118. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308 6921 (1994) 81-106
119. Harpaz D., Gottlieb S., Graff E., et al. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 105 6 (1998) 494-499
120. Bray G., Gregg E., Haffner S., et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab Vasc Dis Res 3 3 (2006) 202-215
121. Pi-Sunyer X., Blackburn G., Brancati F.L., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30 6 (2007) 1374-1383
122. Ryan D.H., Espeland M.A., Foster G.D., et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24 5 (2003) 610-628
123. Boyd C.M., Darer J., Boult C., et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294 6 (2005) 716-724
124. Higashi T., Wenger N.S., Adams J.L., et al. Relationship between number of medical conditions and quality of care. N Engl J Med 356 24 (2007) 2496-2504
125. Blaum C.S. Descriptive epidemiology of diabetes. In: Munshi M.N., and Lipsitz L.A. (Eds). Geriatric diabetes (2007), Informa Healthcare USA, Inc, New York 1-9